Lilly Asia Ventures and Johnson & Johnson Innovation – JJDC are both investing in a series A round for the cell therapy developer, a spinoff from Genscript Biotech.
Legend Biotech Corporation, a cellular therapy subsidiary of China-based biotech producer Genscript Biotech, has agreed to raise approximately $151m from investors including pharmaceutical firms Eli Lilly and Johnson & Johnson.
Hudson Bay Capital Management’s, HBC Asia Healthcare Opportunities III fund, Capital Group’s Smallcap World Fund, Vivo Capital and RA Capital’s Healthcare Fund, Nexus Fund and Blackwell Partners vehicle are also participating in the round, designated as a series A.
The corporates are taking part through corporate venturing vehicles Lilly Asia…